Press Releases

All News
By Year:
2020
2019
2018
2017
2016
2015
2014
2013
2012

Jun 30, 2020 7:00 AM EDT Can-Fite Announces Final Data Analysis from Phase II NASH Study: Highly Significant and Sustained Reduction in Liver Fat Volume Throughout Study Period
Jun 10, 2020 8:00 AM EDT Can-Fite Announces $8.0 Million Registered Direct Offering
Jun 9, 2020 7:00 AM EDT Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S.
Jun 8, 2020 7:25 AM EDT Can-Fite Participating in BIO Digital International Convention and One-on-One Partnering Meetings on June 8-12, 2020
Jun 4, 2020 7:14 AM EDT Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer
Jun 3, 2020 7:00 AM EDT Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on June 4th
Jun 1, 2020 7:00 AM EDT Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update
May 28, 2020 7:00 AM EDT Can-Fite to Host First Quarter 2020 Financial Results & Clinical Update Conference Call on June 1, 2020
May 21, 2020 7:00 AM EDT Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office
May 18, 2020 7:00 AM EDT Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis
May 15, 2020 7:00 AM EDT Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe Symptoms
Apr 14, 2020 7:00 AM EDT Can Fite to Conduct Investor Call to Review Positive Phase II NASH Data on Thursday, April 16, 2020 at 4:05 p.m. ET
Apr 13, 2020 6:30 AM EDT Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately
Apr 7, 2020 9:00 AM EDT Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson
Mar 30, 2020 7:00 AM EDT Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020
Mar 27, 2020 7:00 AM EDT Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update
Mar 23, 2020 7:45 AM EDT Can-Fite: Piclidenoson is Submitted for Compassionate Use Treatment for Coronavirus Patients in Israel
Mar 18, 2020 7:00 AM EDT Can-Fite to Participate in Digital Bio-Europe Spring Partnering Conference; Looks to Partner on Co-Development of Piclidenoson for Coronavirus Treatment
Mar 16, 2020 7:00 AM EDT Can-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson
Mar 13, 2020 7:00 AM EDT Can-Fite to Explore the anti-Coronavirus Effects of Piclidenoson in Collaboration with Lewis Katz School of Medicine at Temple University
Mar 11, 2020 7:30 AM EDT Can-Fite: New Pre-clinical Studies Demonstrate Inhibition of Fat Cell Expansion by Cannabis Derived CBD
Mar 5, 2020 7:00 AM EST Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus
Mar 3, 2020 7:00 AM EST Can-Fite is Filing Drug Safety Update Report Showing Positive Safety Results from Phase II and Phase III Studies of Namodenoson and Piclidenoson
Feb 27, 2020 6:00 AM EST Pre-clinical Studies Demonstrate CBD’s Robust Anti-Cancer Effect Against Liver Cancer; Can-Fite and Univo Pharmaceuticals Expand Collaboration Agreement
Feb 24, 2020 7:00 AM EST Can Fite Files Patent for Namodenoson to Overcome Drug Resistance to Checkpoint Inhibitors for Oncology Indications
Feb 18, 2020 7:10 AM EST Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South Korea; Results of its NASH Phase II Study are Expected this Quarter
Feb 13, 2020 7:00 AM EST Can-Fite Submits Liver Cancer Phase III Protocol and Registration Plan to EMA for Namodenoson
Feb 10, 2020 2:48 PM EST Can-Fite BioPharma Announces Pricing of $5 Million Public Offering
Feb 3, 2020 7:30 AM EST Can-Fite Completes 50% Patient Enrollment in Phase III Rheumatoid Arthritis Study & Implements Interim Analysis
Jan 16, 2020 7:00 AM EST Can-Fite and Univo Pharmaceuticals Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations with Broad Therapeutic Effects
Jan 9, 2020 9:10 AM EST Can-Fite Announces Exercise of Warrants for Cash Proceeds of $2.4 Million
Jan 7, 2020 8:20 AM EST Data from the Phase II Liver Cancer Study with Namodenoson will be presented at the ISCORT Conference by Dr. Stemmer
Jan 6, 2020 7:00 AM EST Can-Fite CEO Issues Letter to Shareholders
Jan 3, 2020 7:00 AM EST New Data From Hadassah Medical Center Lab Show Can-Fite’s Namodenoson Induces Weight Loss
Dec 26, 2019 7:00 AM EST Golan Bitton Univo Pharmaceutical CEO Elected to the Can-Fite Board: A Strategic Partnership with Univo to Develop Cannabinoid-Based Products is Ongoing
Dec 9, 2019 8:15 AM EST Can-Fite Completes 50% Patient Enrollment in its Phase III Psoriasis Trial
Dec 5, 2019 7:00 AM EST Can-Fite to Attend BioFIT 2019 Conference in Europe with Focus on Partnering Meetings for Namodenoson in NASH
Nov 29, 2019 7:00 AM EST Can-Fite Reports Third Quarter 2019 Financial Results & Provides Clinical Update
Nov 21, 2019 7:00 AM EST Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on November 25, 2019
Nov 19, 2019 7:00 AM EST Can-Fite Granted Patents for its Sexual Dysfunction Drug
Nov 11, 2019 7:00 AM EST Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health Market
Nov 4, 2019 7:00 AM EST Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients
Oct 31, 2019 7:00 AM EDT U.S. FDA Agreed with Can-Fite’s Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer
Oct 17, 2019 8:00 AM EDT Can-Fite and Gebro Pharma holding European Conference on Development & Commercialization of Phase III Drug Candidate Piclidenoson in the Treatment of Rheumatoid Arthritis
Oct 16, 2019 7:00 AM EDT Can-Fite BioPharma Interview to Air on Bloomberg International on the RedChip Money Report
Oct 15, 2019 6:30 AM EDT Can-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson™
Oct 10, 2019 7:00 AM EDT Can Fite Announces Publication of Namodenoson™ NASH Mechanism of Action in International Journal of Molecular Medicine
Sep 23, 2019 7:00 AM EDT Can-Fite Presents New Data on the Treatment of Advanced Liver Cancer with Namodenoson at the ILCA Conference
Sep 10, 2019 6:03 AM EDT Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays
Sep 5, 2019 7:00 AM EDT Can-Fite to Present at H. C. Wainwright 21st Annual Global Investment Conference on September 10, 2019
Aug 29, 2019 7:00 AM EDT Can-Fite Reports Second Quarter 2019 Financial Results & Provides Clinical Update
Aug 6, 2019 7:00 AM EDT Can-Fite to Treat Advanced Liver Cancer Patients with Namodenoson Under Compassionate Use Setting in Israel
Aug 1, 2019 8:45 AM EDT Can-Fite Signs Agreement with Kyongbo Pharm for the Distribution in South Korea of Piclidenoson in the Treatment of Psoriasis
Jun 4, 2019 7:00 AM EDT Can-Fite Participating in One-on-One Partnering Meetings at the BIO International Convention on June 3-6, 2019
Jun 3, 2019 7:00 AM EDT Findings from Can-Fite’s Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session
May 29, 2019 7:00 AM EDT Can-Fite Reports First Quarter 2019 Financial Results & Provides Clinical Update
May 23, 2019 7:00 AM EDT The Anti-NASH Effect of Namodenoson will be Presented at the International Conference on Fatty Liver in Berlin
May 20, 2019 2:06 PM EDT Can-Fite BioPharma Announces $6 Million Registered Direct Offering
May 20, 2019 7:00 AM EDT Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)
May 6, 2019 7:00 AM EDT Can-Fite Announces Preparation for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Namodenoson
May 1, 2019 4:05 PM EDT Can-Fite Announces ADS Ratio Change
Apr 15, 2019 7:00 AM EDT Can-Fite Receives $1,000,000 Payment from CKD for Distribution of Namodenoson in South Korea
Apr 10, 2019 7:07 AM EDT Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson™ Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting
Apr 2, 2019 9:00 AM EDT Can-Fite BioPharma Announces $3.2 Million Registered Direct Offering
Mar 29, 2019 4:30 PM EDT Can-Fite Files Annual Report for the Year Ended December 31, 2018
Mar 28, 2019 7:00 AM EDT Can-Fite Reports 2018 Financial Results & Provides Clinical Update
Mar 26, 2019 7:00 AM EDT Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson
Feb 27, 2019 7:00 AM EST Can-Fite to Participate in Bio Asia International Conference on March 5-6, 2019 in Tokyo
Feb 25, 2019 7:00 AM EST Can-Fite Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication
Feb 4, 2019 7:00 AM EST Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis Drug
Jan 30, 2019 7:00 AM EST Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal
Jan 24, 2019 7:30 AM EST Can-Fite BioPharma CEO Letter to Shareholders
Jan 18, 2019 8:00 AM EST Can-Fite BioPharma Announces Registered Direct Offering
Jan 8, 2019 8:00 AM EST Can-Fite: Pre-Clinical Data Positions Namodenoson as an anti-Obesity Agent
Jan 3, 2019 8:02 AM EST Can-Fite to Participate in the Biotech Showcase™ 2019 and BIO One-on-One Partnering™@ JPM 2019 During the JP Morgan Healthcare Conference
Dec 10, 2018 7:00 AM EST Can-Fite Enters Into Collaboration Agreement to Explore Namodenoson’s Anti-NASH Effect With Icahn School of Medicine at Mount Sinai in NYC
Nov 30, 2018 7:00 AM EST Can-Fite Reports Third Quarter 2018 Financial Results and Provides Clinical Development Update
Nov 20, 2018 7:00 AM EST Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert
Oct 31, 2018 7:00 AM EDT Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19
Oct 25, 2018 7:00 AM EDT Can-Fite to Present on its Liver Cancer Drug Namodenoson at the NYC Oncology Investor Conference
Oct 18, 2018 7:00 AM EDT Can-Fite CEO to present as Expert Speaker on Namodenoson at NASH Summit Europe 2018
Sep 12, 2018 7:00 AM EDT Can-Fite to Present the Anti-Fibrogenic Effects of Namodenoson at the Hepatic Fibrosis Conference of the American Association for the Study of Liver Diseases (AASLD)
Sep 4, 2018 7:00 AM EDT Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected by End of Year
Aug 31, 2018 7:00 AM EDT Can-Fite Reports Second Quarter 2018 Financial Results and Provides Clinical Update
Aug 29, 2018 7:00 AM EDT Can-Fite BioPharma Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
Aug 21, 2018 7:00 AM EDT Can-Fite Announces Enrollment of First Patient in its Comfort™ Phase III Trial of Piclidenoson in Psoriasis
Aug 7, 2018 9:14 AM EDT Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China
Aug 6, 2018 5:54 AM EDT Can-Fite Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical
Jul 17, 2018 7:00 AM EDT Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug
Jul 2, 2018 7:00 AM EDT Drugs with Mechanism of Action Utilized by Namodenoson Are Recommended by Leading U.S. Researchers to Be Developed to Combat Liver Cancer
Jun 19, 2018 7:00 AM EDT Can-Fite Updates on Status of Phase II Advanced Liver Cancer Trial
Jun 11, 2018 7:00 AM EDT Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson
Jun 1, 2018 7:00 AM EDT Can-Fite Reports First Quarter 2018 Financial Results and Provides Clinical Update
Apr 25, 2018 7:00 AM EDT Can-Fite's Piclidenoson Mechanism of Action in Psoriasis Published in 'Journal of Immunology Research'
Apr 9, 2018 7:00 AM EDT Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL)
Mar 28, 2018 7:00 AM EDT Can-Fite to Present at the MicroCap Conference
Mar 23, 2018 7:00 AM EDT Can-Fite Reports 2017 Financial Results & Provides Clinical Update
Mar 14, 2018 7:00 AM EDT Can-Fite to Present at the NASH 2nd Annual H.C. Wainwright Investor Conference
Mar 9, 2018 9:00 AM EST Can-Fite BioPharma Announces $5 Million Registered Direct Offering
Mar 6, 2018 7:00 AM EST Can-Fite to Participate in Panel Discussions on Latest Drug Developments in NASH at the 30th Annual ROTH Conference
Mar 5, 2018 7:00 AM EST Can-Fite to Present at the Inaugural LD Micro Virtual Conference
Feb 28, 2018 9:25 AM EST Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson
Feb 22, 2018 8:00 AM EST Can Fite Announces the Submission of Safety Reports for Piclidenoson and Namodenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile
Feb 12, 2018 7:00 AM EST Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson
Jan 31, 2018 7:00 AM EST Can-Fite to Present at BIO CEO & Investor Conference
Jan 25, 2018 7:00 AM EST Can-Fite Receives from Gebro Holdings $2,200,000 Payment as Part of Distribution Agreement for Piclidenoson in 3 European Countries
Jan 11, 2018 7:00 AM EST Can-Fite 12 Months' Activities & Milestones for 2018
Jan 8, 2018 7:40 AM EST Can-Fite Signs Multi-Million Dollar Distribution Agreement for Piclidenoson in 3 European Countries with Gebro Holdings
Jan 3, 2018 7:00 AM EST Can-Fite Enters into Collaborative Research Agreement with Hadassah Medical Center to Further Explore Namodenoson Mechanism of Action in NASH
Dec 18, 2017 7:00 AM EST Can-Fite Reports on the Progress of Its Phase II Liver Cancer with Namodenoson
Nov 27, 2017 7:30 AM EST Can-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update
Nov 27, 2017 7:00 AM EST Can-Fite Enrolls First Patient in Phase II NAFLD/NASH Study with Namodenoson
Nov 17, 2017 7:00 AM EST Can-Fite’s Former Subsidiary OphthaliX Successfully Completes Merger with Wize Pharma
Oct 30, 2017 9:50 AM EDT Can-Fite Announces Enrollment of First Patient in its ACRobat Phase III Trial of Piclidenoson in Rheumatoid Arthritis
Oct 17, 2017 7:00 AM EDT Can-Fite Issued Patent in Korea for Piclidenoson in the Treatment of Psoriasis
Oct 16, 2017 7:00 AM EDT Can-Fite to Present at 2017 AASLD Liver Meeting Conference in Washington, D.C.
Oct 9, 2017 7:00 AM EDT Can-Fite CEO Dr. Pnina Fishman to Present as Expert Speaker at NASH Summit Europe in Frankfurt, Germany on October 12, 2017
Sep 18, 2017 7:00 AM EDT Can-Fite Files Patent Application to Treat Cytokine Release Syndrome, a Potentially Life-Threatening Complication of CAR-T Cell Therapy
Sep 1, 2017 7:00 AM EDT Can-Fite Reports Second Quarter 2017 Financial Results & Provides Clinical Update
Aug 23, 2017 7:00 AM EDT Can-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution Partner in Korea
Aug 9, 2017 7:00 AM EDT Can-Fite Completes Patient Enrolment for its Phase II Study of Namodenoson in the Treatment of Liver Cancer
Aug 7, 2017 7:00 AM EDT Can-Fite Successfully Completes Human Cardiodynamic Safety Trial for Piclidenoson
Jul 17, 2017 7:00 AM EDT Can-Fite’s Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment Following Conclusion of Successful Clinical Investigator Meeting
Jun 15, 2017 7:00 AM EDT Can-Fite to Participate in Bio International Convention in San Diego on June 19-22, 2017
Jun 8, 2017 7:00 AM EDT Can-Fite Concludes Successful Clinical Investigator Meeting for its ACRobat Phase III Trial of Piclidenoson in the Treatment of Rheumatoid Arthritis
Jun 5, 2017 7:00 AM EDT Can-Fite Establishes Clinical Advisory Board for NAFLD/NASH
Jun 1, 2017 7:00 AM EDT New Preclinical Data on Can-Fite's Namodenoson to be Presented at 1st International Conference on Fatty Liver in Seville, Spain on June 2, 2017
May 30, 2017 7:00 AM EDT Can-Fite Reports First Quarter 2017 Financial Results & Provides Clinical Update
May 16, 2017 7:00 AM EDT Can-Fite Files Clinical Trial Application in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis Phase III Study
May 3, 2017 7:00 AM EDT Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH
Apr 25, 2017 7:00 AM EDT Can-Fite's Phase III ACRobat Trial in Rheumatoid Arthritis Approved by Institutional Review Board
Mar 31, 2017 7:00 AM EDT Can-Fite Reports 2016 Financial Results & Provides Clinical Update
Feb 28, 2017 7:00 AM EST New Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis
Feb 8, 2017 7:00 AM EST Can-Fite Gears Up for ACRobat, its Phase III Trial of Piclidenoson in Rheumatoid Arthritis
Jan 19, 2017 7:29 AM EST Can-Fite BioPharma Announces $5 Million Registered Direct Offering
Jan 9, 2017 7:00 AM EST Can-Fite Receives IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial in Q1 2017
Dec 21, 2016 7:00 AM EST Can-Fite Receives $500,000 Payment as Part of $3 Million Distribution Deal for Liver Cancer Drug Namodenoson (CF102) in South Korea
Dec 16, 2016 7:00 AM EST New Preclinical Data Show Can-Fite's Namodenoson (CF102) Inhibits Liver Fibrosis -- Supports Potential Efficacy in Treatment of NASH
Nov 25, 2016 7:00 AM EST Can-Fite Reports Financial Results for Nine Months Ended September 30, 2016 & Provides Clinical Update
Nov 16, 2016 7:00 AM EST American Medical Association's USAN & World Health Organization's INN Approve "Namodenoson" as Generic Name for Can-Fite's Liver Drug CF102
Nov 9, 2016 7:00 AM EST Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Erectile Dysfunction Drug
Nov 7, 2016 7:00 AM EST Can-Fite to Participate in BIO-Europe Partnering Conference on November 7-9, 2016 in Cologne, Germany
Nov 1, 2016 7:00 AM EDT Can-Fite Advances Towards a Pivotal Phase III Clinical Trial in Psoriasis with Piclidenoson (CF101) Following Reaching Agreement with EMA
Oct 25, 2016 7:15 AM EDT Can-Fite Signs Distribution Deal for Liver Cancer Drug CF102 in South Korea
Oct 13, 2016 7:00 AM EDT Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH
Sep 20, 2016 7:00 AM EDT Can-Fite Reports New Data on CF102's Liver Protective & Regenerative Properties Published in Scientific Journal
Sep 13, 2016 7:00 AM EDT Can-Fite Receives Notice of Allowance for Psoriasis Patent in Europe Ahead of Phase III Trial
Sep 7, 2016 7:00 AM EDT Can-Fite to Present at Rodman & Renshaw Conference in New York City on September 12, 2016
Aug 26, 2016 7:00 AM EDT Can-Fite Reports Financial Results for Six Months Ended June 30, 2016
Aug 8, 2016 7:00 AM EDT Can-Fite's Phase II/III Psoriasis Study Results Published in Journal of Drugs in Dermatology
Jul 25, 2016 7:00 AM EDT Can-Fite Completes Phase II Study Design for CF102 in the Treatment of NASH/NAFLD
Jul 5, 2016 7:00 AM EDT OphthaliX Announces Phase II Glaucoma Data
Jun 15, 2016 7:00 AM EDT Can-Fite Reports New Data Showing its Psoriasis Drug May Offer Efficacy Similar to Industry Leading Biologics Without Harmful Side Effects
Jun 7, 2016 7:00 AM EDT Can-Fite Submits Psoriasis Phase III Protocol and Registration Plan to EMA for Piclidenoson (CF101)
Jun 3, 2016 1:50 PM EDT Can-Fite to Exhibit at Bio International Convention in San Francisco on June 6-9, 2016
Jun 1, 2016 7:00 AM EDT Can-Fite Reaches Agreement with EMA on Pivotal Phase III Clinical Trial with Piclidenoson (CF101) in Rheumatoid Arthritis
May 27, 2016 7:00 AM EDT Can-Fite Reports First Quarter 2016 Financial Results & Provides Clinical Pipeline Update
May 2, 2016 7:00 AM EDT Can-Fite to Present Data on CF602 in the Treatment of Erectile Dysfunction at American Urology Association's Annual Meeting
Apr 29, 2016 7:00 AM EDT Can-Fite to Present at Joseph Gunnar & Co.'s Pioneers 2016 Conference in New York City on May 5, 2016
Apr 11, 2016 7:00 AM EDT Can-Fite Announces New Pre-Clinical Data for CF602 Demonstrating Statistically Significant Full Recovery from Erectile Dysfunction After a Single Dose
Apr 4, 2016 7:00 AM EDT Can-Fite to Participate in BIO-Europe Partnering Conference on April 4-6, 2016 in Stockholm, Sweden
Apr 1, 2016 7:00 AM EDT Can-Fite Reports 2015 Financial Results & Provides Clinical Pipeline Update
Mar 17, 2016 7:00 AM EDT Can-Fite Submits Phase III Protocol Design and Registration Plan to European Medicines Agency (EMA) for CF101 in the Treatment of Rheumatoid Arthritis
Mar 3, 2016 7:00 AM EST Can-Fite to Present Psoriasis Data at American Academy of Dermatology's 74th Annual Meeting in Washington D.C. on March 7, 2016
Feb 5, 2016 7:00 AM EST Can-Fite to Present at BIO CEO & Investor Conference in New York City on February 8, 2016
Jan 25, 2016 7:00 AM EST Can-Fite CEO Dr. Pnina Fishman to Chair Scientific Session at the 2016 Purinergic Signaling and Cancer Immunotherapy Conference in Vancouver on January 26, 2016
Jan 19, 2016 7:00 AM EST U.S. Patent & Trademark Office Issues Notice of Allowance for Can-Fite's Sexual Dysfunction Drug CF602
Jan 11, 2016 7:00 AM EST Can-Fite Announces 2016 Clinical Milestones for its Pipeline of Drugs in Six Indications
Jan 8, 2016 7:00 AM EST Can-Fite to Present at Biotech Showcase in San Francisco on January 13, 2016
Jan 5, 2016 7:00 AM EST Can-Fite Submits Phase III Protocol to IRB for CF101 in the Treatment of Rheumatoid Arthritis
Dec 17, 2015 7:00 AM EST Can-Fite's CF101 Granted Patent in Japan for Intraocular Pressure a Key Cause of Glaucoma
Dec 7, 2015 7:00 AM EST Can-Fite Subsidiary, OphthaliX, Announces Completion of Patient Enrollment in Phase II Glaucoma Study for CF101
Nov 27, 2015 7:00 AM EST Can-Fite Reports Financial Results for Nine Months Ended September 30, 2015
Nov 23, 2015 7:00 AM EST Can-Fite Announces Compelling Pre-Clinical Data on CF102 in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Oct 26, 2015 7:00 AM EDT Can-Fite to Participate in BIO-Europe Partnering Conference on November 2-5, 2015 in Munich, Germany
Oct 22, 2015 7:00 AM EDT New Study Demonstrates CF602 Mechanism of Action to Improve Sexual Dysfunction
Oct 13, 2015 8:00 AM EDT Can-Fite BioPharma Announces $4.8 Million Registered Direct Offering
Oct 12, 2015 7:00 AM EDT European Medicines Agency Grants Orphan Designation to Can-Fite's CF102 in the Treatment of Liver Cancer
Oct 7, 2015 7:00 AM EDT Can-Fite to Deliver 2 Presentations on its Cancer Drug CF102 at the 20th World Congress on Advances in Oncology and 18th International Symposium on Molecular Medicine on October 8-10, 2015 in Athens
Sep 29, 2015 10:11 AM EDT Can-Fite to Present CF101 Psoriasis Data at Late Breaking Session of the EADV Congress in Copenhagen on October 10, 2015
Sep 24, 2015 1:49 PM EDT Can-Fite BioPharma Closes $9 Million Registered Direct Offering
Sep 19, 2015 11:56 PM EDT Can-Fite BioPharma Announces $9 Million Registered Direct Offering
Sep 17, 2015 7:00 AM EDT U.S. Food and Drug Administration Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer
Sep 1, 2015 7:00 AM EDT Can-Fite to Present at Rodman & Renshaw 17th Annual Global Investment Conference on September 9, 2015
Aug 27, 2015 5:29 PM EDT Can-Fite Reports Financial Results for Six Months Ended June 30, 2015
Jul 29, 2015 7:00 AM EDT World Health Organization Accepted "Piclidenoson" as Proposed New Generic Name for Can-Fite's Lead Drug Candidate CF101
Jul 23, 2015 7:00 AM EDT Can-Fite Joins Israeli Life Sciences Delegation to Japan on July 28 - 30, 2015
Jun 29, 2015 7:00 AM EDT Can-Fite's CF602 Sexual Dysfunction Drug Backed by New Preclinical Data Progresses Towards an IND
Jun 19, 2015 7:00 AM EDT Can-Fite Subsidiary OphthaliX Signs Definitive Agreement to Acquire Improved Vision Systems Ltd.
Jun 15, 2015 7:00 AM EDT Can-Fite to Exhibit at Bio International Convention in Philadelphia on June 15 - 18, 2015
Jun 10, 2015 7:00 AM EDT Can-Fite Granted Notice of Allowance for Patent Covering Manufacturing Process of CF101 in the U.S.
May 29, 2015 7:00 AM EDT Can-Fite Reports First Quarter 2015 Results
May 11, 2015 7:00 AM EDT Can-Fite's Phase II Liver Cancer Trial Approved in Europe
May 4, 2015 8:50 AM EDT Can-Fite subsidiary, OphthaliX, Signs Term Sheet to Acquire Improved Vision Systems Ltd.
Apr 27, 2015 7:00 AM EDT Can-Fite Reports Positive Results from Further Analysis of Phase II/III Psoriasis Trial
Apr 20, 2015 7:00 AM EDT Can-Fite Applies for Orphan Drug Designation in Europe for CF102 in the Treatment of Liver Cancer
Mar 30, 2015 9:11 AM EDT Can-Fite Reports Top-Line Results from Phase II/III Trial for CF101 in Treatment of Psoriasis
Mar 27, 2015 4:29 PM EDT Can-Fite Files 2014 Annual Report on Form 20-F
Mar 23, 2015 7:00 AM EDT Can-Fite Signs Multi-Million Dollar Distribution Agreement for CF101 in Canada with Cipher Pharmaceuticals
Mar 18, 2015 7:00 AM EDT Can-Fite Completes Development of Commercial Biomarker Test to Predict Patients' Response to Company Drugs
Feb 17, 2015 7:00 AM EST Can-Fite Receives Notice of Allowance in U.S. for Psoriasis Patent
Feb 4, 2015 7:00 AM EST Can-Fite Completes Phase II/III Trial for CF101 in Treatment of Psoriasis
Jan 27, 2015 7:00 AM EST Can-Fite's CF602 Demonstrates Efficacy in Treatment of Sexual Dysfunction in Preclinical Studies
Jan 6, 2015 7:15 AM EST Can-Fite Announces Upcoming 2015 Clinical Milestones for its Pipeline of Drugs in 4 Indications
Dec 30, 2014 7:00 AM EST Can-Fite Completes the Design of the Rheumatoid Arthritis Phase III Study of Its Lead Drug Candidate CF101
Dec 22, 2014 7:00 AM EST Can-Fite Doses First Patient in Global Phase II Liver Cancer Trial for CF102
Dec 15, 2014 7:02 AM EST Second Part of the Glaucoma Phase II study has been Approved in a European Country
Dec 9, 2014 7:00 AM EST Can-Fite to Initiate the Development Program of its Next Generation Drug CF602
Dec 2, 2014 5:49 PM EST Can-Fite Announces $8 Million At-The-Market Registered Direct Offering
Dec 1, 2014 7:00 AM EST US Researchers Published Scientific Findings that are a Potential Breakthrough for Prevention of Neuropathic Pain by CF101
Dec 1, 2014 7:00 AM EST Can-Fite Reports Financial Results for Nine Months Ended September 30, 2014
Nov 18, 2014 7:00 AM EST Can-Fite Near-Term Milestones Timetable for 2014/2015
Nov 17, 2014 5:48 PM EST Can-Fite Announces Special General Meeting of Shareholders to Elect External Director
Nov 13, 2014 7:00 AM EST Can-Fite CEO Dr. Pnina Fishman to Present Recently Released Positive Data from its Rheumatoid Arthritis Phase IIb Study at the 2014 American College of Rheumatology Annual Meeting
Oct 30, 2014 7:00 AM EDT Can-Fite to Participate in BIO-Europe International Partnering Conference
Oct 7, 2014 7:00 AM EDT Can-Fite CEO Dr. Pnina Fishman to Co-Chair and Present at the 19th World Congress on Advances in Oncology's Cancer Therapeutics Session
Sep 30, 2014 7:00 AM EDT U.S. Patent and Trademark Office Issues Can-Fite Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery
Sep 17, 2014 3:02 PM EDT Can-Fite Files June 30, 2014 Interim Financial Statements
Sep 17, 2014 7:00 AM EDT Can Fite's Drug CF101 is Presented in Scientific Journal as One of Four Small Molecule Drugs for the Treatment of Psoriasis
Sep 5, 2014 7:00 AM EDT Can-Fite Issued Japanese Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery
Sep 3, 2014 7:00 AM EDT Can-Fite to Present at Rodman & Renshaw Global Investment Conference in New York City on September 9, 2014
Sep 2, 2014 7:00 AM EDT Can-Fite Reports First Six Months 2014 Results
Aug 6, 2014 7:00 AM EDT New Data Shows High Efficacy for Can-Fite's CF101 in Rheumatoid Arthritis and Psoriasis Patients
Jul 21, 2014 7:00 AM EDT Can-Fite CEO to Deliver Scientific Presentation and Serve on Expert Panel at Purines 2014 in Bonn, Germany on July 23-27, 2014
Jul 10, 2014 7:00 AM EDT Can-Fite's CF102 Approved for Compassionate Use in Israel for Liver Cancer Patient
Jun 19, 2014 7:00 AM EDT Can-Fite to Exhibit at Bio International Convention in San Diego on June 23 - 26, 2014
Jun 17, 2014 7:00 AM EDT Can-Fite Completes Patient Enrollment in its Phase II/III Psoriasis Trial; Final Results are expected in Q1 2015
Jun 10, 2014 7:00 AM EDT Can-Fite to Participate in Newport Coast Securities Conference in New York & ROTH Conference in London
Jun 9, 2014 7:00 AM EDT Can-Fite Subsidiary OphthaliX Provides an Update on its Clinical Developments and Strategic Plans
Jun 2, 2014 7:00 AM EDT Can-Fite Announces that the US FDA has Agreed with its Phase II Liver Cancer Protocol
May 30, 2014 4:32 PM EDT Can-Fite Announces 2014 Annual General Meeting
May 29, 2014 7:00 AM EDT Can-Fite Reports First Quarter 2014 Results
May 15, 2014 7:00 AM EDT Can-Fite to Exhibit at MIXiii Biomed Israel Innovation Conference
May 7, 2014 11:41 AM EDT Can-Fite Receives Patent in European Union for Treatment of Liver Function Following Surgery
Apr 29, 2014 7:00 AM EDT Can-Fite Submits Protocol to U.S. FDA for Phase II Liver Cancer Study
Apr 21, 2014 7:00 AM EDT Can-Fite Initiates the Development of an A3AR Biomarker Test Kit to Predict Patients' Response to Company's Drugs
Mar 31, 2014 2:28 PM EDT Can-Fite Files 2013 Annual Report on Form 20-F
Mar 25, 2014 7:00 AM EDT Can-Fite to Present at the 9th International Congress of Autoimmunity
Mar 17, 2014 7:00 AM EDT ‏Can-Fite: Phase II Study Protocol to Treat Patients with Advanced Liver Cancer with CF102 has been Approved by the IRB in Israel
Mar 10, 2014 12:44 PM EDT Can-Fite Completes $5 Million Private Placement
Mar 3, 2014 7:00 AM EST Can-Fite Announces the Addition of A Key Opinion Leader to Boost its Rheumatoid Arthritis CF101 Program
Feb 27, 2014 7:00 AM EST Can-Fite to Present at the 26th Annual ROTH Capital Conference
Feb 25, 2014 7:00 AM EST Can-Fite Granted Patent on the Manufacturing of CF101 in Japan
Feb 18, 2014 7:00 AM EST Can-Fite Provides Update on Key Milestones for 2014
Feb 11, 2014 7:00 AM EST Can-Fite Comments on Global Rheumatoid Arthritis Market Opportunity
Feb 6, 2014 7:00 AM EST ‏Can-Fite Submitted Phase II Study Protocol with CF102 to Treat Patients with Advanced Liver Cancer
Jan 13, 2014 7:00 AM EST Can-Fite to Present New Clinical Data from Further Analysis of its Clinical Studies of CF101 for the Treatment of Rheumatoid Arthritis and Psoriasis at OneMedForum and Biotech Showcase held in San Francisco, California
Jan 7, 2014 7:00 AM EST Can-Fite to Present at Two Upcoming Healthcare Investor Conferences
Dec 31, 2013 7:00 AM EST OphthaliX to Retrospectively Analyze Phase III Dry Eye Syndrome Study Data Based on A3 Adenosine Receptor Biomarker
Dec 30, 2013 1:00 AM EST OphthaliX Announces Top-Line Results of Phase III Study with CF101 for Dry Eye Syndrome
Dec 23, 2013 7:00 AM EST Can-Fite BioPharma Announces Top-Line Results of Phase IIb Study with CF101 as a Monotherapy for Rheumatoid Arthritis
Dec 19, 2013 7:00 AM EST Can-Fite Granted U.S. Patent for Utilization of A3 Adenosine Receptor as Biomarker to Predict Patient Response to CF101 in Autoimmune Inflammatory Indications
Dec 11, 2013 7:00 AM EST Can-Fite CEO Issues Letter to Shareholders
Dec 5, 2013 7:00 AM EST Can-Fite Anticipates Results from Two Clinical Trials
Dec 2, 2013 7:00 AM EST Can-Fite CEO to Ring Opening Bell at New York Stock Exchange
Nov 20, 2013 7:00 AM EST Can-Fite BioPharma Generates Partnership Interest at Therapeutic Area Partnerships Conference in Boston
Nov 15, 2013 7:00 AM EST Can-Fite BioPharma Announces Approval of ADR Listing on NYSE MKT
Nov 11, 2013 7:00 AM EST Can-Fite BioPharma to Conduct U.S. Road Show on November 18 - 21, 2013
Nov 5, 2013 1:08 PM EST U.S. Patent and Trademark Office Grants a Patent for the Reduction of Intraocular Pressure
Nov 5, 2013 7:00 AM EST Can-Fite BioPharma to Conduct European Road Show
Nov 4, 2013 7:30 AM EST Can-Fite Executes Confidentiality Agreements with Pharmaceutical and Biotechnology Companies with Respect to Potential CF101 Commercialization Negotiations
Oct 25, 2013 7:00 AM EDT Can-Fite BioPharma Successfully Concludes $6,000,000 Public Offering With an Over-Subscription of 300%
Oct 22, 2013 3:10 PM EDT Can-Fite BioPharma Announces Clinical and Corporate Developments for Near-Term Events
Oct 15, 2013 7:00 AM EDT Can-Fite BioPharma's CF101 Drug Selected as one of the "Top Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Elsevier Business Intelligence
Oct 10, 2013 7:00 AM EDT Can-Fite BioPharma to Present Its Liver Cancer Drug at the 18th World Congress on Advances in Oncology in Greece
Oct 2, 2013 7:00 AM EDT Can-Fite's Subsidiary OphthaliX to Present at Ophthalmology Futures European Forum
Sep 23, 2013 7:00 AM EDT Can-Fite CEO Pnina Fishman Interviewed on CorporateProfile.com
Sep 12, 2013 8:19 AM EDT Can-Fite's Level II ADRs Commence Trading on the U.S. OTC Markets
Sep 3, 2013 1:38 PM EDT Can-Fite to Present at Rodman & Renshaw Global Investment Conference on September 9, 2013
Aug 28, 2013 11:12 AM EDT Can-Fite to Initiate a Phase II Study With CF102 in 130 Patients With Advanced Liver Cancer
Feb 5, 2013 9:52 AM EST Can-Fite Announces Successful Completion of its Public Offering
Nov 13, 2012 10:00 AM EST Can-Fite BioPharma to Develop a Drug for the Treatment of Sexual Dysfunction
Oct 9, 2012 12:00 AM EDT Interim Analysis Supports Continuation of Can-Fite's Phase 2/3 Psoriasis Clinical Study with CF101
Oct 4, 2012 8:00 AM EDT Can-Fite BioPharma Begins Trading in U.S. through Launch of ADRs

Homepage \| Contact us	only canfite.com